FDA Approves Imlunestrant and Abemaciclib Combination
FDA approved imlunestrant plus abemaciclib for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, detected by an FDA-authorized test, after progression on at least one endocrine-therapy line. FDA simultaneously approved Guardant360 CDx…
